Jyong Biotech

Healthy Life Biotech develops plant-based drugs: MCS-2 for benign prostatic hyperplasia and MCS-8 for prostate cancer prevention.

Healthy Life Biotech develops plant-based drugs: MCS-2 for benign prostatic hyperplasia and MCS-8 for prostate cancer prevention.

Healthy Life Biotech develops plant-based drugs: MCS-2 for benign prostatic hyperplasia and MCS-8 for prostate cancer prevention.

Jyong Biotech advances its market access strategy for its botanical drug pipeline, including **Botreso®** and **PCP**, following clinical efficacy and competitive advantage assessments. The company refines regulatory and commercialization approaches to accelerate adoption of its science-driven plant-based therapies. Jyong Biotech remains focused on translating research into scalable botanical treatments for unmet medical needs.

Apr 2026yam.comNews article

Jyong Biotech Ltd. raises **$20 million** through its initial public offering (IPO) on Nasdaq under the ticker **MENS**. The Taiwan-based biotech company specializes in **plant-derived drugs**, initially targeting **urinary system diseases** for markets in the **U.S., EU, and Asia**. The offering includes **2.67 million ordinary shares** as part of its science-driven commercialization strategy.

Jun 2025Yahoo FinanceNews article

Jyong Biotech Ltd. debuts on the stock market with its IPO opening at **$15 per share**, following an initial pricing of **$7.50**. The company’s shares trade at more than double the set valuation on the first day of trading. Investors respond strongly to the biotech firm’s market entry, reflecting confidence in its potential.

Jun 2025Investing.comNews article

Jyong Biotech’s stock price doubles on its first day of trading on the Nasdaq exchange. The biotech company’s debut marks its entry into U.S. markets, reflecting investor interest in its offerings. No specific details about the company’s products or financials are provided in the report.

Jun 2025Investing.comNews article